Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779679 | 1.00 | ODC1 (0.47) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL2614685 | 1.00 | ODC1 (0.47) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL23779684 | 1.00 | ODC1 (0.47) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL17110675 | 0.97 | ODC1 (0.45) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL62175 | 0.97 | — | — | |
| SCHEMBL6051828 | 0.93 | ODC1 (0.47) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL10796626 | 0.93 | ODC1 (0.47) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL25842 | 0.93 | ODC1 (0.53) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL18756832 | 0.93 | ODC1 (0.53) | ODC1NFKB1CYP3A4CA12CA1 | |
| SCHEMBL11126194 | 0.93 | ODC1 (0.53) | ODC1NFKB1CYP3A4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091491-B2 | Silylamine compound and latent curing agent comprising said silylamine compound | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| CN-112930352-B | Silylamine compounds and latent curing agents containing the same | 广荣化学株式会社 | 2024-02-13 | — | — | CN | disclosed |
| US-20220119583-A1 | SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3875461-A1 | SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND | Koei Chemical Company, Limited (JP) | 2021-09-08 | — | — | EP | disclosed |
| CN-112930352-A | Silylamine compound and latent curing agent containing the same | 广荣化学株式会社 | 2021-06-08 | — | — | CN | disclosed |
| US-9303114-B2 | One liquid type cyanate ester-epoxy composite resin composition | ADEKA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9303114-B2 | One liquid type cyanate ester-epoxy composite resin composition | ADEKA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-8445706-B2 | Unnatural amino acids capable of covalently modifying protein phosphatases and their use as general and specific inhibitors and probes | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120123082-A1 | ONE LIQUID TYPE CYANATE ESTER-EPOXY COMPOSITE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120123082-A1 | ONE LIQUID TYPE CYANATE ESTER-EPOXY COMPOSITE RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20100061936-A1 | UNNATURAL AMINO ACIDS CAPABLE OF COVALENTLY MODIFYING PROTEIN PHOSPHATASES AND THEIR USE AS GENERAL AND SPECIFIC INHIBITORS AND PROBES | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY | 2010-03-11 | — | — | US | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-5240499-A | Polymeric pigments | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-31 | — | — | US | disclosed |
| EP-0492501-A1 | Surface-active triazine compounds, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | ODC1 4837/4885NFKB1 750/4885CYP3A4 4036/4885 |
| US-20220119583-A1 | SILYLAMINE COMPOUND AND LATENT CURING AGENT COMPRISING SAID SILYLAMINE COMPOUND | CDKN1A, SIRT2, H1-4 | ODC1 745/4885NFKB1 697/4885CYP3A4 271/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | ODC1 4784/4885NFKB1 510/4885CYP3A4 3634/4885 |
| US-12091491-B2 | Silylamine compound and latent curing agent comprising said silylamine compound | CDKN1A, SIRT2, H1-4 | ODC1 745/4885NFKB1 697/4885CYP3A4 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.